KalVista Pharmaceuticals Inc.

KALV

⚠ Showing the latest available close (Jun 12, 2026, 146 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1.44B

EPS-$3.63

P/E-7.44

P/FCF–

EV/EBITDA–

FCF Yield–

Div. Yield–

Net Debt/FCF–

KalVista Pharmaceuticals Inc. intrinsic value

52-Week Range

$10.78$27.00

Profitability & Returns

TTM as of 2026-03 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$191M

Op. Margin

–

ROIC

–

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF

N/A

Op. Cash Flow

N/A

Net Debt

-$101M

Net Cash Position

Cash & Equiv.

$285M

5Y CAGR: +87.9%

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with KALV

CompareIntrinsic value

XOMAXOMA Corporation

€0.05-3.60%64

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

SPROSpero Therapeutics Inc.

$1.07+2.88%63

GOSSGossamer Bio Inc.

$9.40+1.29%10

SIGASiga Technologies Inc.

$3.15+1.29%20

QTTBQ32 Bio Inc.

$8.97+2.40%60

TNGXTango Therapeutics Inc.

$23.18+0.04%40

Held by ETFs

KALV is in 3 US ETFs. The largest of them, with KALV's weight in each:

KalVista Pharmaceuticals (KALV) in three numbers

Quality score: 25/100; Best check: revenue growth, 81.3%. Weakest: share count change, 428.8%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -7.44; Negative: a loss over the last twelve months.; Financials

Questions about KalVista Pharmaceuticals

Is KalVista Pharmaceuticals a high-quality business?

KalVista Pharmaceuticals scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is revenue growth at 81.3%, and its weakest is share count change at 428.8%. The Quality tab shows every check against its target.

Does KalVista Pharmaceuticals (KALV) pay a dividend?

No. KalVista Pharmaceuticals (KALV) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 7 May 2026 (period ending 31 Mar 2026), SEC. Price: last close 12 Jun 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in KALV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KALV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.